A phase 1 trial in Nature Medicine reports that the personalised NeoVax vaccine combined with nivolumab was feasible and had an acceptable safety profile in ovarian cancer.
Trending
- Saturn’s Moon Count Leaps to 274 After 128 New Moons Are Confirmed
- Personalised Cancer Vaccine Shows Promise on Safety in Early Ovarian Trial
- Microsoft Docs Warned Its AI Was Starting a ‘Doom Loop’ That Could Gut the Web
- SpaceX Launch Paints a Stunning Jellyfish Cloud Over the US East Coast
- A Safer Public Wi-Fi Approach
- Maniformer Presents MEgoVista, a Metric-Scale 4D Hand and Head Motion Reconstruction System
- Wearable Health Tech in 2026: From Step Counts to Early Warnings That Matter
- Is Yono Arcade Safe? Safety, Legitimacy and Fair Play Explained
Friday, October 16